VJET 8-K
Flyte Aviation, Inc. (VJET)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On November 15, 2021, Ra Medical Systems, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2021. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
|
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
RA MEDICAL SYSTEMS, INC. |
|
|
|
|
|
|
|
Date: November 15, 2021 |
|
By: |
|
/s/ Andrew Jackson |
|
|
|
|
|
Andrew Jackson |
|
|
|
|
|
Chief Financial Officer |
|
|
|
|
|
(Principal Financial and Accounting Officer) |
Exhibit 99.1
Ra Medical Systems Reports 2021 Third Quarter Financial Results
Conference call begins at 4:30 p.m. Eastern time today
CARLSBAD, Calif. (November 15, 2021) – Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on developing its excimer laser system to treat vascular disease, reports financial results for the three and nine months ended September 30, 2021 and provides a business update.
Recent Operational Highlights
|
|
• |
Completed the sale of the Pharos dermatology business for net cash proceeds of $3.5 million as part of the continued focus by the company of its resources on the large peripheral artery disease (PAD) market |
|
|
• |
Added two new sites and enrolled 15 additional subjects in the company’s atherectomy pivotal clinical study since mid-August, for a total of 85 subjects enrolled to date in the 100-subject study |
|
|
• |
Continued exploring the potential for the DABRA technology to create shock waves that can fracture arterial calcium, sometimes referred to as intravascular lithotripsy |
“We are reporting progress on all key initiatives,” said Will McGuire, Ra Medical Systems CEO. “First, the clinical team drove strong enrollment in our pivotal clinical study to obtain an atherectomy indication. Second, we advanced our engineering efforts to develop more robust, deliverable DABRA catheters and we continue to expect to submit an application to the FDA next quarter seeking regulatory clearance for the first next-gen catheter. Third, I continue to be excited about our research work showing the DABRA laser system can be utilized to create shockwaves of sufficient magnitude to fracture calcium in arteries commonly referred to as intravascular lithotripsy, which we believe represents a potential to create significant shareholder value.
“Finally, I want to commend the Ra Medical team for executing the divestiture of our dermatology business. As previously stated, we believe focusing our resources on the large and growing market for medical devices to treat PAD is the best path to creating shareholder value. An estimated 19 million to 21 million people in the U.S. have PAD and the market segments we are targeting are projected to exceed $900 million in revenue this year,” added Mr. McGuire.
Third Quarter Financial Highlights
Continuing Operations
Net revenue for the third quarter of 2021 consisted of product sales of $5,000. This compares with net revenue from continuing operations for the third quarter of 2020 of $68,000, which consisted of product sales of $66,000 and service and other revenue of $2,000.
Total cost of revenue for the third quarter of 2021 was $0.2 million, compared with $0.6 million for the third quarter of 2020.
Selling, general and administrative expenses for the third quarter of 2021 were $4.2 million, which included $0.1 million in stock-based compensation, compared with $4.7 million for the third quarter of 2020, which included $0.8 million in stock-based compensation. Research and development expenses for the third quarter of 2021 were $2.9 million, which included $27,000 in stock-based compensation, compared with $2.3 million for the third quarter of 2020, which included $0.1 million in stock-based compensation.
The loss from continuing operations for the third quarter of 2021 was $7.4 million, or $1.15 per share on 6.4 million weighted-average shares outstanding, compared with a loss for the third quarter of 2020 of $7.5 million, or $3.15 per share on 2.4 million weighted-average shares outstanding.
Adjusted EBITDA for the third quarter of 2021 was negative $6.9 million, compared with negative $6.1 million for the third quarter of 2020. Adjusted EBITDA is a non-GAAP measure presented as loss from continuing operations before depreciation and amortization expense, interest income, interest expense, income taxes, stock-based compensation, gain and loss from sales and disposals of property and equipment, and gain on extinguishment of the Paycheck Protection Program (PPP) promissory note. For additional information regarding the non-GAAP financial measures discussed in this news release, please see "Non-GAAP Reconciliations" below.
Discontinued Operations
Net revenue for the third quarter of 2021 of $0.5 million consisted of product sales of $0.1 million and service and other revenue of $0.4 million. This compares with net revenue for the third quarter of 2020 of $0.8 million which consisted of product sales of $0.1 million and service and other revenue of $0.7 million.
Total cost of revenue for the third quarter of 2021 was $0.4 million, compared with $0.9 million for the third quarter of 2020.
Selling, general and administrative expenses for the third quarter of 2021 were $0.3 million compared with $0.2 million for the third quarter of 2020. Research and development expenses for the third quarter of 2021 were $0.1 million compared with $21,000 for the third quarter of 2020.
The loss from discontinued operations for the third quarter of 2021 was $0.4 million compared with a loss for the third quarter of 2020 of $0.3 million.
The gain on sale of the dermatology business for the third quarter of 2021 was $3.5 million.
The income/loss from discontinued operations, including the gain on sale of the dermatology business, for the third quarter of 2021 was income of $3.1 million, or $0.48 per share on 6.4 million weighted-average shares outstanding, compared with a loss for the third quarter of 2020 of $0.3 million, or $0.11 per share on 2.4 million weighted-average shares outstanding.
Nine Month Financial Highlights
Continuing Operations
Net revenue for the first nine months of 2021 consisted of product sales of $17,000. This compares with net revenue for the first nine months of 2020 of $0.3 million which consisted primarily of product sales.
Total cost of revenue for the first nine months of 2021 was $1.2 million, compared with $1.7 million for the first nine months of 2020.
Selling, general and administrative expenses for the first nine months of 2021 were $11.3 million, which included $1.6 million in stock-based compensation, compared with $18.2 million for the first nine months of 2020, which included $2.4 million in stock-based compensation. Research and development expenses for the first nine months of 2021 were $8.5 million, which included $0.3 million in stock-based compensation, compared with $5.5 million for the first nine months of 2020, which included $0.3 million in stock-based compensation.
The loss from continuing operations for the first nine months of 2021 was $19.0 million, or $4.23 per share on 4.5 million weighted-average shares outstanding, compared with a loss for the first nine months of 2020 of $25.1 million, or $19.32 per share on 1.3 million weighted-average shares outstanding.
Adjusted EBITDA for the first nine months of 2021 was negative $18.6 million, compared with negative $20.8 million for the first nine months of 2020. For additional information regarding the non-GAAP financial measures discussed in this news release, please see "Non-GAAP Reconciliations" below.
Ra Medical reported cash and cash equivalents of $20.6 million as of September 30, 2021.
2
Nine Month Financial Highlights
Discontinued Operations
Net revenue for the first nine months of 2021 was $2.6 million which consisted of product sales of $0.9 million and service and other revenue of $1.7 million. This compares with net revenue for the first nine months of 2020 of $2.9 million which consisted of product sales of $0.7 million and service and other revenue of $2.2 million.
Total cost of revenue for the first nine months of 2021 was $2.3 million, compared with $2.4 million for the first nine months of 2020.
Selling, general and administrative expenses for the first nine months of 2021 were $1.1 million compared with $1.0 million for the first nine months of 2020. Research and development expenses for the first nine months of 2021 were $0.4 million compared with $47,000 for the first nine months of 2020.
The loss from discontinued operations for the first nine months of 2021 was $1.3 million compared with a loss for the first nine months of 2020 of $0.5 million.
The gain on sale of the dermatology business for the first nine months of 2021 was $3.5 million.
The income/loss from discontinued operations, including the gain on sale of the dermatology business, for the first nine months of 2021 was income of $2.2 million, or $0.49 per share on 4.5 million weighted-average shares outstanding, compared with a loss for the third quarter of 2020 of $0.5 million, or $0.40 per share on 1.3 million weighted-average shares outstanding.
Ra Medical will hold a conference call and audio webcast to discuss this announcement and answer questions at 4:30 p.m. Eastern time today. The conference call dial-in numbers are 866-777-2509 for domestic callers and 412-317-5413 for international callers, and the passcode is 10157984. A live webcast of the call will be available on the Investor Relations section of www.ramed.com.
A recording of the call will be available for 48 hours beginning approximately two hours after the completion of the call by dialing 877-344-7529 for domestic callers, 855-669-9658 for Canadian callers or 412-317-0088 for international callers. Please use the passcode 10157984. A webcast replay will be available on the Investor Relations section of www.ramed.com for 30 days, beginning approximately two hours after the completion of the call.
Non-GAAP Financial Measures
Ra Medical has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three- and nine-month periods ended September 30, 2021 and September 30, 2020. EBITDA and Adjusted EBITDA are performance measures that provide supplemental information management believes is useful to analysts and investors to evaluate Ra Medical’s ongoing results of operations, when considered alongside other GAAP measures. These measures are intended to aid investors in better understanding Ra Medical’s current financial performance and prospects for the future as seen through management. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Management believes that these non-GAAP financial measures facilitate comparisons with Ra Medical’s historical results and with the results of peer companies who present similar measures (although other companies may define non-GAAP measures differently than we define them, even when similar terms are used to identify such measures). Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Ra Medical encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business.
3
Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this news release.
Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business. Ra Medical defines EBITDA as our GAAP loss from continuing operations as adjusted to exclude depreciation and amortization, interest income, interest expense and income tax expense. Ra Medical defines Adjusted EBITDA as EBITDA adjusted to exclude stock-based compensation, gain on extinguishment of PPP promissory note and loss (gain) on sales and disposals of property and equipment.
About Ra Medical Systems
Ra Medical Systems manufactures the DABRA excimer laser and catheters for the treatment of vascular diseases. DABRA has been cleared by the FDA for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and has an intended use for ablating a channel in occlusive peripheral vascular disease. In addition, DABRA has been granted CE mark clearance for the endovascular treatment of infrainguinal arteries via atherectomy and for crossing total occlusions. DABRA breaks down plaque to its fundamental chemistry, such as proteins, lipids and other chemical compounds, eliminating blockages by essentially dissolving them without generating potentially harmful particulates. DABRA excimer lasers and catheters are manufactured in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in clean room environments.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Ra Medical’s future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding Ra Medical’s business strategy, the potential of the DABRA system for new applications of use, the market opportunity and growth of current and potential markets and its ability to continue to manage expenses and cash burn rate at sustainable levels. Ra Medical’s expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, challenges inherent in developing, manufacturing, launching, marketing, and selling new products or new applications of use; risks associated with acceptance of DABRA devices for current and potential applications of use and procedures performed using such devices by physicians, payors, and other third parties; development and acceptance of new products, product enhancements or applications of use; clinical and statistical verification of the benefits achieved via the use of Ra Medical’s products; the results from our clinical trials, which may not support intended indications or may require Ra Medical to conduct additional clinical trials or modify ongoing clinical trials; challenges related to commencement, patient enrollment, completion, an analysis of clinical trials; Ra Medical’s ability to manage operating expenses; Ra Medical’s ability to recruit and retain management and key personnel; Ra Medical’s need to comply with complex and evolving laws and regulations; intense and increasing competition and consolidation in Ra Medical’s industry; the impact of rapid technological change; adverse outcome of regulatory inspections; and the other risks and uncertainties described in Ra Medical’s news releases and filings with the Securities and Exchange Commission. Information on these and additional risks, uncertainties, and other information affecting Ra Medical’s business and operating results is contained in Ra Medical’s Annual Report on Form 10-K for the year ended December 31, 2020 and in its other filings with the Securities and Exchange Commission. Additional information is also set forth in Ra Medical’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law.
4
Ra Medical investors and others should note that we announce material information to the public about the company through a variety of means, including our website (www.ramed.com), our investor relations website (https://ir.ramed.com/), press releases, SEC filings and public conference calls in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.
Contacts
At the Company:
Andrew Jackson
Chief Financial Officer, Ra Medical Systems
760-496-9540
[email protected]
Investors:
LHA Investor Relations
Jody Cain
310-691-7100
5
Ra Medical Systems, Inc.
(Unaudited)
(in thousands)
|
|
|
September 30, 2021 |
|
|
December 31, 2020 |
|
||
|
ASSETS |
|
|
|
|
|
|
|
|
|
Current Assets |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
20,616 |
|
|
$ |
23,906 |
|
|
Accounts receivable, net |
|
|
17 |
|
|
|
24 |
|
|
Inventories |
|
|
997 |
|
|
|
877 |
|
|
Prepaid expenses and other current assets |
|
|
1,169 |
|
|
|
1,100 |
|
|
Current assets of discontinued operations |
|
|
— |
|
|
|
1,713 |
|
|
Total current assets |
|
|
22,799 |
|
|
|
27,620 |
|
|
Property and equipment, net |
|
|
2,030 |
|
|
|
2,527 |
|
|
Operating lease right-of-use-assets |
|
|
2,205 |
|
|
|
2,484 |
|
|
Other long-term assets |
|
|
45 |
|
|
|
45 |
|
|
Long-term assets of discontinued operations |
|
|
— |
|
|
|
762 |
|
|
TOTAL ASSETS |
|
$ |
27,079 |
|
|
$ |
33,438 |
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
543 |
|
|
$ |
471 |
|
|
Accrued expenses |
|
|
2,632 |
|
|
|
4,147 |
|
|
Current portion of operating lease liabilities |
|
|
301 |
|
|
|
356 |
|
|
Current portion of equipment financing |
|
|
— |
|
|
|
265 |
|
|
Current portion of PPP promissory note |
|
|
— |
|
|
|
421 |
|
|
Current liabilities of discontinued operations |
|
|
— |
|
|
|
2,102 |
|
|
Total current liabilities |
|
|
3,476 |
|
|
|
7,762 |
|
|
Operating lease liabilities |
|
|
2,054 |
|
|
|
2,264 |
|
|
PPP promissory note |
|
|
— |
|
|
|
1,579 |
|
|
Long-term liabilities of discontinued operations |
|
|
— |
|
|
|
686 |
|
|
Total liabilities |
|
|
5,530 |
|
|
|
12,291 |
|
|
Total stockholders’ equity |
|
|
21,549 |
|
|
|
21,147 |
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
27,079 |
|
|
$ |
33,438 |
|
6
Ra Medical Systems, Inc.
Condensed Statements of Operations
(Unaudited)
(in thousands, except per share data)
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
|
Net revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product sales |
|
$ |
5 |
|
|
$ |
66 |
|
|
$ |
17 |
|
|
$ |
254 |
|
|
Service and other |
|
|
— |
|
|
|
2 |
|
|
|
— |
|
|
|
5 |
|
|
Total net revenues |
|
|
5 |
|
|
|
68 |
|
|
|
17 |
|
|
|
259 |
|
|
Cost of revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product sales |
|
|
68 |
|
|
|
323 |
|
|
|
676 |
|
|
|
1,131 |
|
|
Service and other |
|
|
178 |
|
|
|
245 |
|
|
|
537 |
|
|
|
615 |
|
|
Total cost of revenues |
|
|
246 |
|
|
|
568 |
|
|
|
1,213 |
|
|
|
1,746 |
|
|
Gross loss |
|
|
(241 |
) |
|
|
(500 |
) |
|
|
(1,196 |
) |
|
|
(1,487 |
) |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
4,211 |
|
|
|
4,695 |
|
|
|
11,285 |
|
|
|
18,154 |
|
|
Research and development |
|
|
2,942 |
|
|
|
2,312 |
|
|
|
8,521 |
|
|
|
5,534 |
|
|
Total operating expenses |
|
|
7,153 |
|
|
|
7,007 |
|
|
|
19,806 |
|
|
|
23,688 |
|
|
Operating loss |
|
|
(7,394 |
) |
|
|
(7,507 |
) |
|
|
(21,002 |
) |
|
|
(25,175 |
) |
|
Other income (expense), net |
|
|
16 |
|
|
|
(8 |
) |
|
|
2,028 |
|
|
|
97 |
|
|
Loss from continuing operations before income taxes |
|
|
(7,378 |
) |
|
|
(7,515 |
) |
|
|
(18,974 |
) |
|
|
(25,078 |
) |
|
Income taxes |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Loss from continuing operations |
|
|
(7,378 |
) |
|
|
(7,515 |
) |
|
|
(18,974 |
) |
|
|
(25,078 |
) |
|
Discontinued operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations (including gain on sale of $3,500 in 2021) before income taxes |
|
|
3,080 |
|
|
|
(264 |
) |
|
|
2,191 |
|
|
|
(523 |
) |
|
Income taxes |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Income (loss) from discontinued operations |
|
|
3,080 |
|
|
|
(264 |
) |
|
|
2,191 |
|
|
|
(523 |
) |
|
Net loss |
|
$ |
(4,298 |
) |
|
$ |
(7,779 |
) |
|
$ |
(16,783 |
) |
|
$ |
(25,601 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income per share, basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
(1.15 |
) |
|
$ |
(3.15 |
) |
|
$ |
(4.23 |
) |
|
$ |
(19.32 |
) |
|
Discontinued operations |
|
|
0.48 |
|
|
|
(0.11 |
) |
|
|
0.49 |
|
|
|
(0.40 |
) |
|
Total net loss per share, basic and diluted |
|
$ |
(0.67 |
) |
|
$ |
(3.26 |
) |
|
$ |
(3.74 |
) |
|
$ |
(19.72 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted weighted average common shares outstanding |
|
|
6,415 |
|
|
|
2,386 |
|
|
|
4,487 |
|
|
|
1,298 |
|
7
Ra Medical Systems, Inc.
Non-GAAP Reconciliations
(Unaudited)
(in thousands)
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
|
Statements of Operations Data: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations |
|
$ |
(7,378 |
) |
|
$ |
(7,515 |
) |
|
$ |
(18,974 |
) |
|
$ |
(25,078 |
) |
|
Depreciation and amortization |
|
|
319 |
|
|
|
528 |
|
|
|
974 |
|
|
|
1,530 |
|
|
Interest income |
|
|
— |
|
|
|
(4 |
) |
|
|
(2 |
) |
|
|
(128 |
) |
|
Interest expense |
|
|
— |
|
|
|
12 |
|
|
|
12 |
|
|
|
31 |
|
|
Income tax expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
EBITDA |
|
|
(7,059 |
) |
|
|
(6,979 |
) |
|
|
(17,990 |
) |
|
|
(23,645 |
) |
|
Stock-based compensation |
|
|
110 |
|
|
|
919 |
|
|
|
1,887 |
|
|
|
2,867 |
|
|
Gain on extinguishment of PPP promissory note |
|
|
— |
|
|
|
— |
|
|
|
(2,023 |
) |
|
|
— |
|
|
Loss (gain) on sales and disposals of property and equipment |
|
|
4 |
|
|
|
— |
|
|
|
(489 |
) |
|
|
— |
|
|
Adjusted EBITDA |
|
$ |
(6,945 |
) |
|
$ |
(6,060 |
) |
|
$ |
(18,615 |
) |
|
$ |
(20,778 |
) |
8